CompletedNCT03839251
Long-Acting Aripiprazole in Recent-Onset or Chronic Schizophrenia
About this title
Read the official source — NCT03839251Medication studyAges 19–60South Korea
Understand this study
Who was this study for?
Listed age limits: 19 years to 60 years.
- Listed locations
- Busan and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: June 1, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 82
- Sponsor
- Chonbuk National University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- South Korea
- Age range
- From 19 Years to 60 Years
- Official registry ID
- NCT03839251
- Official title
Show the full official title
Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Busan · Daegu · Gwangju
1 more locations
- Jeonju
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Chonbuk National University Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including abilify maintena.
Who was this study for?
Listed age limits: 19 years to 60 years.
